AbbVie

Dublin, Dublin, IRL
50,000 Total Employees
Year Founded: 2013
View Website

Similar Companies Hiring

InterSystems Logo

InterSystems

Artificial Intelligence • Big Data • Healthtech • Machine Learning • Software • Database • Analytics
37 Offices
2407 Employees
Pfizer Logo

Pfizer

Artificial Intelligence • Healthtech • Machine Learning • Natural Language Processing • Biotech • Pharmaceutical
19 Offices
121990 Employees

AbbVie Company Stability & Growth

Updated on October 14, 2025

This page was generated by Built In using publicly available information and AI-based analysis of common questions about the company. It has not been reviewed or approved by the company.

What's the stability & growth outlook for AbbVie?

Strengths in revenue momentum, scale, and multi‑franchise diversification are accompanied by near‑term profitability noise from acquisition‑related charges, competitive pressure in aesthetics, and occasional pipeline setbacks. Together, these dynamics suggest a leader with resilient top‑line growth and strong strategic positioning, albeit with earnings variability as it invests to extend its growth runway.
Positive Themes About AbbVie
  • Strong Revenue Growth: Recent results show net revenues up year over year in 2024 and in Q1–Q2 2025, with trailing twelve‑month revenue also higher; management raised 2025 revenue guidance. Growth is anchored by surging Skyrizi and Rinvoq sales that more than offset Humira declines.
  • Diversified Revenue Streams: Multiple franchises contribute—immunology (Skyrizi/Rinvoq), neuroscience (Vraylar, Botox Therapeutic, migraine brands), oncology (Venclexta, Elahere), and aesthetics—while numerous acquisitions and partnerships broaden future sources. This mix reduces reliance on any single product and supports continued topline momentum.
  • Strong Market Position & Advantage: The company ranks among the top global pharma by revenue and market capitalization and holds leading positions in immunology and medical aesthetics. Such scale and category leadership underpin bargaining power, access, and resilience.
Considerations About AbbVie
  • Declining Profitability: Adjusted earnings guidance for 2025 was reduced following a large acquired IPR&D write‑off, and GAAP EPS has been pressured by deal‑related charges. These items create near‑term earnings volatility even as sales grow.
  • Weak Market Position & Pricing Challenges: Aesthetics revenues declined amid economic headwinds and intensifying competition, indicating price sensitivity and share pressure in that segment. Humira’s continued erosion from biosimilars also reflects competitive pressures in immunology.
  • Innovation Gaps: Select pipeline setbacks (e.g., charges tied to discontinued or underperforming programs) highlight development risk despite overall portfolio strength. Such outcomes can weigh on near‑term financials while the broader pipeline matures.
NEW
What does AI tell candidates about your employer brand?
Get your free AI reputation report today.
See AI Report
AI Report
AI Report
The insights on this page are generated by submitting structured prompts to some of the most popular large language models (“LLMs”) and summarizing recurring themes from the responses. Because the insights are generated using AI, they may contain errors. The insights do not necessarily reflect internal data, employee interviews, or verified company information. They may be influenced by incomplete, outdated, or inaccurate data, and may vary across LLM providers. These insights are intended for informational purposes only and should not be interpreted as a factual or definitive assessment of a company's reputation. Built In makes no representations or warranties regarding the accuracy, completeness, or reliability of this information, and disclaims any liability for any actions taken based on this information. If you are a representative of this company, and would like this page to be removed, you may contact us via this form.
Is This Your Company? Claim Profile